American Regent v. Zydus Cadila: Selenious Acid IV Patent Suit Consolidated
American Regent, Inc. filed suit against Zydus Cadila in the District of New Jersey asserting US11998565B2 over intravenous selenious acid selenium products. Within 128 days, the case was consolidated with 13 parallel ANDA actions brought against major generic pharmaceutical companies, all proceeding under a single caption.
ARI’s broad ANDA campaign targets 14 generic selenium IV makers
American Regent, Inc. filed this infringement action against Zydus Cadila on July 16, 2024 in the U.S. District Court for the District of New Jersey, asserting U.S. Patent No. 11,998,565 B2 covering intravenous selenious acid products used in parenteral nutrition. The accused products are Zydus’s selenious acid solutions for intravenous use in three concentrations: 12 mcg/2 mL, 60 mcg/mL, and 600 mcg/10 mL — each mirroring ARI’s own branded Selenious Acid product line.
On October 22, 2024, the court entered a consolidation order terminating this docket as a standalone action. All parties consented, and the case was merged with 13 parallel infringement actions brought by ARI against defendants including Accord Healthcare, Cipla, Dr. Reddy’s Laboratories, Hikma, Sun Pharmaceutical, and others. All proceedings now continue under lead case No. 2:24-cv-07791. No merits determination — on infringement, validity, or damages — has been recorded in this docket.
The 128-day period from filing to consolidation suggests ARI moved efficiently to coordinate litigation across a large defendant cohort, consistent with a coordinated ANDA enforcement strategy. The breadth of the defendant list — 14 companies in total — suggests multiple generic manufacturers filed ANDAs referencing ARI’s selenious acid NDA around the same period. The public record for this individual docket is silent on claim construction, any Paragraph IV certification details, or whether any defendant has asserted invalidity counterclaims.
Filing to Case Consolidated in 128 days
128 days — resolved at consolidation order, faster than typical ANDA district court timelines
Case consolidated: what the transfer to lead docket means for both parties
Consolidation merges dockets — no dismissal or merits ruling
Case consolidation under Fed. R. Civ. P. 42(a) combines actions sharing common questions of law or fact into a single proceeding. This docket was not dismissed — it was absorbed into lead case 2:24-cv-07791. All claims, defenses, and parties from this action continue to exist; they are simply litigated alongside 13 other defendants. No finding on infringement, validity, or damages has been made.
Procedural — no merits adjudicatedARI gains litigation efficiency across 14 generic defendants
Consolidation typically benefits a plaintiff managing parallel ANDA suits by reducing duplicative discovery, aligning claim construction proceedings, and lowering per-case legal costs. ARI can now pursue coordinated infringement arguments across all defendants simultaneously. The 30-month ANDA stay clock, if triggered, would run consistently across the consolidated action, preserving ARI’s market exclusivity window during litigation.
Plaintiff benefits from unified proceedingsZydus faces coordinated litigation alongside 13 co-defendants
Consolidation means Zydus’s case will be litigated on a schedule set by the lead docket, alongside major generic players including Sun Pharma, Hikma, and Dr. Reddy’s. This can benefit defendants through shared discovery and coordinated invalidity challenges, but also means Zydus has less control over pacing and strategy. The outcome of any lead defendant’s proceedings may set practical precedents affecting Zydus’s position.
Shared discovery, reduced individual controlMulti-defendant ANDA battle will define selenium IV market access
With 14 generic manufacturers simultaneously challenging ARI’s selenious acid franchise, the consolidated litigation will effectively determine when — and whether — generic intravenous selenium products can enter the U.S. market. A finding of validity and infringement in ARI’s favour would extend market exclusivity across all defendants. A successful invalidity challenge by any defendant could open the market to multiple generic entrants simultaneously.
Market entry for all 14 generics at stakeFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | American Regent, Inc. | Company | Pharmaceutical company — holder of US11998565B2 for IV selenious acid productsSearch in Eureka ↗ |
| Defendant | Zydus Cadila | Individual | Generic pharmaceutical manufacturer targeting ARI’s intravenous selenium product lineSearch in Eureka ↗ |
| Plaintiff counsel | Charles H. Chevalier | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Christine A. Gaddis | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Dennies Varughese | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Gibbons PC | Law Firm | Representing American Regent, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Sterne Kessler Goldstein & Fox | Law Firm | Representing American Regent, Inc.Search in Eureka ↗ |
| Defendant counsel | Zhibin Li | Attorney | Counsel for Zydus CadilaSearch in Eureka ↗ |
| Defendant law firm | Locke Lord LLP | Law Firm | Representing Zydus CadilaSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consolidation order is purely procedural — it reflects judicial efficiency in managing related ANDA infringement actions and does not constitute a ruling on any substantive issue. The order confirms ARI filed 14 separate infringement suits, all of which now proceed together. The scope of US11998565B2’s claims, any validity challenges, and the ultimate question of whether Zydus’s ANDA products infringe remain entirely unresolved at this stage of the consolidated proceedings.
US11998565B2 — Intravenous Selenious Acid Parenteral Nutrition Products
U.S. Patent No. 11,998,565 B2, filed under application No. 18/124,391, covers intravenous selenious acid formulations used to deliver selenium in parenteral nutrition settings. Selenium is an essential trace element administered intravenously to patients who cannot absorb nutrients orally, including critically ill and long-term TPN-dependent patients. The patent’s coverage of multiple concentration variants — 6 mcg/mL, 60 mcg/mL, and 60 mcg/mL per 10 mL — suggests claims directed at formulation parameters or manufacturing specifications across the product line.
The fact that 14 generic manufacturers simultaneously sought to enter this space suggests ARI’s selenious acid products represent a commercially significant injectable micronutrient franchise. For competitors in the parenteral nutrition sector, this patent creates a meaningful barrier to ANDA-based market entry. The breadth of defendants — spanning Indian generics majors, U.S.-based manufacturers, and specialty pharmaceutical companies — reflects the attractiveness of the selenium IV market and the challenge any single generic faces in designing around a formulation patent covering multiple concentration tiers.
Should you run an FTO against US11998565B2 before launching a selenium IV product?
Any company developing, manufacturing, or seeking ANDA approval for intravenous selenious acid products at concentrations of 12 mcg/2 mL, 60 mcg/mL, or 600 mcg/10 mL should treat US11998565B2 as a primary FTO concern. The consolidated litigation confirms ARI is actively enforcing this patent across the full competitive landscape — 14 enforcement actions filed simultaneously is an unusually aggressive posture and signals a well-resourced enforcement strategy.
PatSnap Eureka’s FTO Search Agent can rapidly map the claim landscape of US11998565B2 against your formulation parameters, flag prosecution history estoppel risks, and identify prior art that may support a design-around or invalidity position. Given the consolidated multi-defendant context, Eureka can also surface any IPR petitions filed against this patent and track the lead docket for rulings that may affect your FTO exposure — all in one workflow.
Run a freedom-to-operate analysis on US11998565B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent suits over injectable pharmaceutical formulations
Explore parallel ANDA infringement cases involving injectable formulation patents litigated in the District of New Jersey, including multi-defendant consolidations.
What this case signals for the parenteral nutrition IP landscape
ARI’s coordinated 14-defendant campaign signals aggressive ANDA enforcement strategy in the injectable micronutrient space.
Multi-defendant ANDA filings signal a crowded generic pipeline for selenium IV
The simultaneous filing of 14 parallel infringement suits suggests multiple companies filed ANDAs referencing ARI’s selenious acid NDA at or near the same time. Companies in the parenteral nutrition or injectable micronutrient space should monitor ANDA activity against branded IV selenium products as a leading indicator of impending patent litigation.
Consolidation accelerates patent outcome — watch the lead docket closely
With all 14 cases merged under 2:24-cv-07791, any ruling on claim construction, summary judgment, or trial verdict in the lead case will functionally bind all defendants including Zydus. IP counsel monitoring this space should track the lead docket for scheduling orders, Markman hearing dates, and any early resolution signals.
American v Zydus — key questions answered
The case was consolidated with 13 parallel actions under lead case 2:24-cv-07791 in the District of New Jersey. No merits ruling on infringement or validity was issued in this docket. All proceedings continue under the consolidated caption.
American Regent asserted U.S. Patent No. 11,998,565 B2 (application No. 18/124,391), covering intravenous selenious acid products used in parenteral nutrition, across three product concentrations: 12 mcg/2 mL, 60 mcg/mL, and 600 mcg/10 mL.
The court consolidated the action because ARI filed 14 substantially similar infringement suits against different generic manufacturers simultaneously, all asserting the same patent over closely related selenium IV products. Consolidation avoids duplicative proceedings and aligns discovery and claim construction across all defendants.
The consolidated action includes Accord Healthcare, Aspiro Pharma, Cipla USA and Cipla Limited, Dr. Reddy’s Laboratories, Eugia Pharma, Gland Pharma, Hikma Pharmaceuticals USA, Long Grove Pharmaceuticals, RK Pharma, Somerset Therapeutics entities, Sun Pharmaceutical Industries, Xiromed entities, and Zydus Pharmaceuticals (USA) Inc.
The dispute centres on intravenous selenious acid solutions for parenteral selenium supplementation. ARI’s products and Zydus’s accused ANDA products both cover three concentrations: 12 mcg/2 mL, 60 mcg/mL (single vial), and 600 mcg/10 mL, all delivering selenium as an injectable micronutrient.
PatSnap Eureka searches patents and litigation data to answer instantly.